{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:52Z","timestamp":1789584892979,"version":"build-2803163510"},"reference-count":53,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Neuroendocrinology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu\u2010edotreotide is a radiopharmaceutical therapy (RPT) targeting somatostatin receptors, which are commonly overexpressed on neuroendocrine tumors (NETs). This systematic literature review and meta\u2010analysis describes the efficacy and safety of [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu\u2010edotreotide in patients with NETs. To date, there has been no meta\u2010analysis of data for this specific RPT. PubMed, EMBASE, Cochrane databases, and abstracts from select congresses were searched for eligible studies (February\/October 2024). Meta\u2010analysis was performed using fixed and random\u2010effects models. The primary objective was to evaluate the efficacy of [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu\u2010edotreotide in terms of objective response rate (ORR; complete + partial response) in the subgroup of patients with gastro\u2010enteropancreatic NETs (GEP\u2010NETs) and those with any NETs, irrespective of origin (All\u2010NETs). Secondary outcomes included disease control rate (DCR; best overall response of complete response + partial response + stable disease), median progression\u2010free survival (mPFS), and median overall survival (mOS). Unpublished\/updated data were requested from the investigators of the included publications where needed to provide missing information\/enable evaluation of additional outcomes. Safety\/tolerability data for [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu\u2010edotreotide were also reviewed. Eight eligible studies were identified for inclusion in the meta\u2010analysis, all in the advanced disease setting (5\/8 included patients with progressive NETs). Most patients had grade 1\/2 NETs (grade 1: 11%\u201363%; 2: 30%\u201379%; 3: 4%\u201311%). Updated data were provided for four of these studies. Overall, ORR and DCR were reported in six studies (GEP\u2010NETs,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009222; All\u2010NETs,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009423), mPFS in five studies (GEP\u2010NETs,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009294; All\u2010NETs,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009267), and mOS in six studies (GEP\u2010NETs,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009256; All\u2010NETs,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009408). Meta\u2010analysis revealed consistently high heterogeneity (\n                    <jats:italic>I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    &gt;70%) across outcomes\/patient populations. Patients with GEP\u2010NETs appeared to have better outcomes than those with All\u2010NETs in terms of ORR (34% vs. 19%), DCR (78% vs. 57%), mPFS (24.9 vs. 18.6\u2009months), and mOS (44.8 vs. 39.1\u2009months), respectively. Safety\/tolerability data were inconsistently reported, but grade 3\/4 toxicities were rarely noted during [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu\u2010edotreotide treatment. These results support the effectiveness and safety of [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu\u2010edotreotide as a treatment for patients with advanced NETs and suggest a potentially more favorable prognosis for those with GEP\u2010NETs than for the broader All\u2010NETs population. However, these results should be interpreted with caution due to the high level of heterogeneity. Encouraging ORRs and high DCRs were noted, indicating that [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu\u2010edotreotide effectively stabilized disease in most patients. Although safety\/tolerability data were inconsistently published across studies, [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu\u2010edotreotide was generally well tolerated. Overall, these findings suggest that the efficacy and safety of [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu\u2010edotreotide are in line with those reported for other RPTs in similar clinical settings.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical Trial Registration<\/jats:bold>\n                    : PROSPERO 2024 CRD42024518028.\n                  <\/jats:p>","DOI":"10.1111\/jne.70103","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T08:43:52Z","timestamp":1762591432000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systematic review and meta\u2010analysis of the efficacy and safety of [\n                    <sup>177<\/sup>\n                    <scp>Lu<\/scp>\n                    ]Lu\u2010edotreotide ([\n                    <sup>177<\/sup>\n                    <scp>Lu<\/scp>\n                    ]Lu\u2010\n                    <scp>DOTATOC<\/scp>\n                    ) for the treatment of neuroendocrine tumors"],"prefix":"10.1111","volume":"38","author":[{"given":"Richard P.","family":"Baum","sequence":"first","affiliation":[{"name":"Advanced Theranostics Center for Radiomolecular Precision Oncology, Deutsche Klinik f\u00fcr Diagnostik (DKD HELIOS Klinik) Curanosticum Wiesbaden\u2010Frankfurt  Wiesbaden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia G.","family":"Fricke","sequence":"additional","affiliation":[{"name":"Department of Theragnostics, Division of Nuclear Medicine, ENETS Centre of Excellence (CoE) University Hospital Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ruhwedel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of the Free University of Berlin and of Humboldt University of Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Amthauer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of the Free University of Berlin and of Humboldt University of Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-461X","authenticated-orcid":false,"given":"Erika Patricia","family":"Azorin\u2010Vega","sequence":"additional","affiliation":[{"name":"Department of Radioactive Materials Instituto Nacional de Investigaciones Nucleares (ININ)  State of Mexico Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"H\u00f6rsch","sequence":"additional","affiliation":[{"name":"Zentralklinik Bad Berka GmbH  Bad Berka Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Laudicella","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morpho\u2010Functional Imaging Nuclear Medicine, University of Messina  Messina Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikalp","family":"Maheshwari","sequence":"additional","affiliation":[{"name":"Parexel International  Hyderabad Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Walter","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, University Hospital Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna Degirmenci","family":"Polack","sequence":"additional","affiliation":[{"name":"ITM SE  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"Spiegl","sequence":"additional","affiliation":[{"name":"ITM SE  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0396-5708","authenticated-orcid":false,"given":"Guillaume P.","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Department of Theragnostics, Division of Nuclear Medicine, ENETS Centre of Excellence (CoE) University Hospital Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379\u2010018\u20100110\u2010y"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.09.002"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29099"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.15798"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912\u2010021\u201001029\u20107"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123049"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.1014"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.941832"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091463"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050034"},{"issue":"5","key":"e_1_2_10_13_1","first-page":"311","article-title":"Somatostatin receptor PET ligands\u2014the next generation for clinical practice","volume":"8","author":"Pauwels E","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20103\u2010642\u201027994\u20102_18"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20103\u2010642\u201027994\u20102_30"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010012\u20102123\u2010y"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010004\u20101553\u20106"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010006\u20100172\u20109"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40658\u2010019\u20100243\u20101"},{"key":"e_1_2_10_20_1","unstructured":"US Food and Drug Administration.Lutathera(Lutetium Lu 177 Dotatate): Prescribing Information. Accessed April 29 2025https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208700s000lbl.pdf"},{"key":"e_1_2_10_21_1","unstructured":"European Medicines Agency.Lutathera(Lutetium[177Lu]Oxodotreotide): European Public Assessment Report(EPAR). Accessed April 29 2025.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lutathera"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041024"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041494"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000019304"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.993182"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013700.pub2"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020358"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040984"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010015\u20103030\u20109"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246290"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040635"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245717"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010025\u201007221\u20102"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13485157"},{"issue":"4","key":"e_1_2_10_37_1","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel N","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197\u20102456(86)90046\u20102"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177729756"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.13702"},{"issue":"8","key":"e_1_2_10_42_1","first-page":"1310","article-title":"Treatment with 177Lu\u2010DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y\u2010DOTATOC","volume":"46","author":"Forrer F","year":"2005","journal-title":"J Nucl Med"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071988"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13469"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.021"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21840"},{"key":"e_1_2_10_47_1","unstructured":"HuangY ZhuJ LiaoY LuoH WenZ.The Therapeutic Efficacy and Safety of177Lu\u2010DOTATOC and90Y\u2010DOTATOC in Neuroendocrine Tumors: A Systematic Review and Meta\u2010Analysis. Accessed March 25 2025.https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022370424"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(21)00572\u20106"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(24)00701\u20103"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201016\u20102743"},{"issue":"1","key":"e_1_2_10_51_1","first-page":"313","article-title":"Efficacy and safety of [177Lu]Lu\u2010edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial","volume":"37","author":"Capdevila J","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"e_1_2_10_52_1","unstructured":"Isotope Technologies Munich (ITM).ITM Announces Positive Topline Results of Phase 3 COMPETE Trial With ITM\u201011 A Targeted Radiopharmaceutical Therapy in Patients With Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors(GEP\u2010NETs). Accessed March 13 2025.https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/1b6a27e0-9dff-42b5-ad0f-fa45f1973508"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1530\/erc\u201018\u20100424"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.90.P117"}],"container-title":["Journal of Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jne.70103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jne.70103","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jne.70103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:48:13Z","timestamp":1777956493000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jne.70103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/jne.70103"],"URL":"https:\/\/doi.org\/10.1111\/jne.70103","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/JNE.70103\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.70103\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.70103\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.70103\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.70103\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.70103\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.70103\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.70103\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.70103\/v2\/review1","asserted-by":"object"}]},"ISSN":["0953-8194","1365-2826"],"issn-type":[{"value":"0953-8194","type":"print"},{"value":"1365-2826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"2025-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70103"}}